Furthermore, by analysing the patient cohorts in the PrognoScan database and Kaplan-Meier Plotter, we found that high SIRT2 expression level was associated with better prognosis (OS or DFS) in brain, colorectal, and lung cancer, while the prognosis in the bladder, breast, and ovarian cancers was the opposite. This evidence concerns the gene SIRT2 and lung carcinoma.